Trial Profile
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Docetaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2012 Planned end date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 08 Nov 2012 Planned end date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.